These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 8612318

  • 21. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
    Souquet PJ, Fournel P, Bohas CH, Fortune IC, Chatte G.
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
    [Abstract] [Full Text] [Related]

  • 22. A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer.
    Kosmas C, Tsavaris N, Koutras A, Makatsoris T, Mylonakis N, Tzelepis G, Dimitrakopoulos A, Spyropoulos K, Polyzos A, Karabelis A, Kalofonos HP.
    Oncology; 2005 Apr; 69(4):333-41. PubMed ID: 16282711
    [Abstract] [Full Text] [Related]

  • 23. A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report.
    Shepherd FA, Goss PE, Latreille J, Stewart D, Logan D, Evans WK, Maroun J, Warner E.
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):19-23. PubMed ID: 2159185
    [Abstract] [Full Text] [Related]

  • 24. Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.
    Feld R, Wierzbicki R, Walde PL, Shepherd FA, Evans WK, Gupta S, Shannon P, Lassus M.
    J Clin Oncol; 1992 Feb; 10(2):297-303. PubMed ID: 1310105
    [Abstract] [Full Text] [Related]

  • 25. Phase I-II study of high dose epirubicin plus cisplatin in unresectable non-small-cell lung cancer: searching for the maximal tolerated dose.
    Quantin X, Rivière A, Daurès JP, Oliver P, Comte-Bardonnet M, Khial F, Marcillac I, Pujol JL.
    Am J Clin Oncol; 2000 Apr; 23(2):192-6. PubMed ID: 10776983
    [Abstract] [Full Text] [Related]

  • 26. Treatment of non-small cell lung cancer with ifosfamide (IFO)+ 4'-epiadriamycin (EPI)+platinum vs. IFO+EPI: a GETLAC Study. Grupo de Estudio y Tratamiento Latinoamericano del Cáncer Study.
    Brocato N, Bruno MF, Araujo CE, Cervellino JC, Pirisi C, Temperley G, Sparrow C, Savulsky C, Balbiani LR.
    Oncology; 1995 Apr; 52(1):24-31. PubMed ID: 7800338
    [Abstract] [Full Text] [Related]

  • 27. Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.
    Shepherd FA, Latreille J, Crump M, Stewart D, Tomiak E, Eisenhauer E, Fisher B.
    Ann Oncol; 1996 Mar; 7(3):311-3. PubMed ID: 8740797
    [Abstract] [Full Text] [Related]

  • 28. A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer.
    Chen YM, Perng RP, Yang KY, Lin WC, Wu HW, Liu JM, Tsai CM, Whang-Peng J.
    Am J Clin Oncol; 2000 Feb; 23(1):13-7. PubMed ID: 10683066
    [Abstract] [Full Text] [Related]

  • 29. Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
    Baka S, Manegold C, Buchholz E, Schott-von-Römer K, Lorigan P, Nagel S, Blackhall F, Aschroft L, Thatcher N.
    Lung Cancer; 2006 Aug; 53(2):165-70. PubMed ID: 16787686
    [Abstract] [Full Text] [Related]

  • 30. Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy.
    Miller VA, Rigas JR, Pisters KM, Grant SC, Pfister DG, Heelan RT, Kris MG.
    Am J Clin Oncol; 1995 Aug; 18(4):303-6. PubMed ID: 7625371
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study.
    Chevallier B, Leyvraz S, Olivier JP, Fargeot P, Facchini T, Vo Van ML.
    Cancer Invest; 1993 Aug; 11(2):135-9. PubMed ID: 8462014
    [Abstract] [Full Text] [Related]

  • 33. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.
    Langenbuch T, Mross K, Jonat W, Hossfeld DK.
    Cancer Chemother Pharmacol; 1990 Aug; 26 Suppl():S93-6. PubMed ID: 2347058
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. High-dose epirubicin for untreated patients with advanced tumours: a phase I study.
    Martoni A, Melotti B, Guaraldi M, Pacciarini MA, Riva A, Pannuti F.
    Eur J Cancer; 1990 Aug; 26(11-12):1137-40. PubMed ID: 1963544
    [Abstract] [Full Text] [Related]

  • 38. Phase II study of high-dose epirubicin in non-small cell lung cancer.
    Wils J, Utama I, Sala L, Smeets J, Riva A.
    Eur J Cancer; 1990 Aug; 26(11-12):1140-1. PubMed ID: 1963545
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.